prikaz prve stranice dokumenta The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
  Download
PDF 459.32 KB
Scientific paper - Original scientific paper
The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
Pediatric Rheumatology, 12 (2014), 1; 50. https://doi.org/10.1186/1546-0096-12-50
Bobek, Dubravka; Grčević, Danka; Kovačić, Nataša; Lukić, Ivan Krešimir; Jelušić, Marija

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Bobek, D., Grčević, D., Kovačić, N., Lukić, I. K. & Jelušić, M. (2014). The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatric Rheumatology, 12. (1), 50. doi: 10.1186/1546-0096-12-50

Bobek, Dubravka, et al. "The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus." Pediatric Rheumatology, vol. 12, no. 1, 2014, p. 50. https://doi.org/10.1186/1546-0096-12-50

Bobek, Dubravka, Danka Grčević, Nataša Kovačić, Ivan Krešimir Lukić and Marija Jelušić. "The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus." Pediatric Rheumatology 12, no. 1 (2014): 50. https://doi.org/10.1186/1546-0096-12-50

Bobek, D., et al. (2014) 'The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus', Pediatric Rheumatology, 12(1), p. 50. doi: 10.1186/1546-0096-12-50

Bobek D, Grčević D, Kovačić N, Lukić IK, Jelušić M. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatric Rheumatology [Internet]. 2014 December 03 [cited 2024 November 23];12(1):50. doi: 10.1186/1546-0096-12-50

D. Bobek, D. Grčević, N. Kovačić, I. K. Lukić and M. Jelušić, "The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus", Pediatric Rheumatology, vol. 12, no. 1, p. 50, December 2014. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:974842. [Accessed: 23 November 2024]

Metadata
Title (english)The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
AuthorDubravka Bobek
AuthorDanka Grčević
AuthorNataša Kovačić
AuthorIvan Krešimir Lukić
AuthorMarija Jelušić
Author's institutionUniversity of Zagreb
School of Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
BACKGROUND: The involvement of high mobility group box-1 (HMGB1) in various inflammatory and autoimmune diseases has been documented but clinical trials on the contribution of this pro-inflammatory alarmin in children with juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE) are basically absent. To address the presence of HMGB1 and a soluble receptor for advanced glycation end products (sRAGE) in different subtypes of JIA and additionally in children with SLE, we enrolled a consecutive sample of children harvested peripheral blood as well as synovial fluids (SF) at diagnosis and correlated it with ordinary acute-phase reactants and clinical markers. ----- METHODS: Serum and synovial fluids levels of HMGB1 and sRAGE in total of 144 children (97 with JIA, 19 with SLE and 27 healthy controls) were determined by ELISA. ----- RESULTS: The children with JIA and those with SLE were characterised by significantly higher serum levels of HMGB1 and significantly lower sRAGE levels compared to the healthy controls. A positive correlation between serum HMGB1 and ESR, CRP, α2 globulin was found while serum sRAGE levels were inversely correlated with the same inflammatory markers in children with JIA. Additionally, high level of serum HMGB1 was related to hepatosplenomegaly or serositis in systemic onset JIA. ----- CONCLUSION: The inverse relationship of the HMGB1 and its soluble receptor RAGE in the blood and SF indicates that inflammation triggered by alarmins may play a role in pathogenesis of JIA as well as SLE. HMGB1 may serve as an inflammatory marker and a potential target of biological therapy in these patients. Further studies need to show whether the determination of HMGB1 levels in patients with JIA can be a useful guideline for detecting disease activity.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titlePediatric Rheumatology
Numberingvol. 12, no. 1, p. 50
p-ISSN1546-0096
DOIhttps://doi.org/10.1186/1546-0096-12-50
URN:NBNurn:nbn:hr:105:974842
Publication2014-12-03
Document URLhttps://doi.org/10.1186/1546-0096-12-50
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-03-27 20:16:02